Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar 15:9:13.
doi: 10.1186/1477-7517-9-13.

Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide

Affiliations

Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide

Veeraindar Goli et al. Harm Reduct J. .

Abstract

Background: Respiratory depression, a potentially fatal side-effect of opioid-overdose, may be reversed by timely administration of an opioid antagonist, such as naloxone or naltrexone. Tampering with a formulation of morphine sulfate and sequestered naltrexone hydrochloride extended release capsules (MS-sNT) releases both the opioid morphine and the antagonist naltrexone. A study in recreational opioid-users indicated that morphine and naltrexone injected in the 25:1 ratio (duplicating the ratio of the formulation) found MS-sNT reduced morphine-induced euphoric effects vs intravenous (IV) morphine alone. In the same study, the effects of morphine + naltrexone on end-tidal carbon dioxide (EtCO2), a measure of respiratory-depression, were evaluated and these data are reported here.

Methods: Single-center, placebo-controlled, double-blind crossover study. Non-dependent male opioid users were randomized to receive single IV doses of placebo, 30 mg morphine alone, and 30 mg morphine + 1.2 mg naltrexone. EtCO2 was measured by noninvasive capnography.

Results: Significant differences in EtCO2 least-squares means across all treatments for maximal effect (Emax) and area under the effect curve (AUE0-2, AUE0-8, AUE0-24) were detected (all p ≤ 0.0011). EtCO2 Emax values for morphine + naltrexone were significantly reduced vs morphine alone (42.9 mm Hg vs 47.1 mm Hg, p < 0.0001) and were not significantly different vs placebo (41.9 mm Hg). Median time to reach maximal effect (TEmax) was delayed for morphine + naltrexone vs morphine alone (5.0 h vs 1.0 h).

Conclusions: Results provide preliminary evidence that the naltrexone:morphine ratio within MS-sNT is sufficient to significantly reduce EtCO2 when administered intravenously to non-dependent male recreational opioid-users. Further studies with multiple measures of respiratory-function are warranted to determine if risk of respiratory depression is also reduced by naltrexone in the tampered formulation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean EtCO2 (mm Hg) ± SEM over 24 hours post-dose (PD population).
Figure 2
Figure 2
Mean pre-dose EtCO2 and post-dose Emax EtCO2 (mm Hg)(PD population). Error bars represent SEMs.

References

    1. Centers for Disease Control and Prevention. QuickStats: number of poisoning deaths involving opioid analgesics and other drugs or substances-United States, 1999-2007. MMWR Morb Mortal Wkly Rep. 2010;59:1026.
    1. Warner M, Chen LH, Makuc DM. National Center for Health Statistics (NCHS) Data Brief. Hyattsville, MD: National Center for Health Statistics; 2009. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006; pp. 1–8. - PubMed
    1. Paulozzi LJ. Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. Am J Public Health. 2006;96:1755–1757. doi: 10.2105/AJPH.2005.071647. - DOI - PMC - PubMed
    1. Paulozzi LJ, Weisler RH, Patkar AA. A national epidemic of unintentional prescription opioid overdose deaths: how physicians can help control it. J Clin Psychiatry. 2011;72:589–592. doi: 10.4088/JCP.10com06560. - DOI - PubMed
    1. Hays L, Kirsh KL, Passik SD. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a sustance abuse treatment facility in Kentucky. J Natl Compr Canc Netw. 2003;1:423–428. - PubMed

LinkOut - more resources